Sign in Subscribe
Cytological research

Blocking ERK-1/2 Reduces TNF-alpha-Induced IL-18 Bioactivity in Rheumatoid Arthritis Synovial Fibroblasts

Strategic Insights

— 1 min read

Recent research published in the journal Arthritis and Rheumatism has shed light on the mechanism of regulation of interleukin-18 (IL-18) bioactivity by IL-18 binding protein (IL-18BP) induction in rheumatoid arthritis (RA) synovial fibroblasts. The study found that blocking ERK-1/2 activity reduces TNF-alpha-induced IL-18 bioactivity in RA synovial fibroblasts by inducing IL-18 binding protein A (IL-18BPa). This finding suggests a potential therapeutic option for managing RA.

Key Takeaways:

  • Blocking ERK-1/2 activity reduces TNF-alpha-induced IL-18 bioactivity in RA synovial fibroblasts by inducing IL-18BPa synthesis.
  • IL-18BPa levels were lower in RA synovial fluid than in osteoarthritis (OA) synovial fluid (p < 0.01).
  • IL-18 and IL-18BPa synthesis in RA synovial fibroblasts treated with proinflammatory cytokines (e.g., TNF-alpha) was assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively.
  • Targeting IL-18 bioactivity by induction or addition of IL-18BPa may provide another therapeutic option in the management of RA.
  • Caspase 1 activity, a key regulator of IL-18, was determined by a colorimetric assay and was found to be induced by TNF-alpha in RA synovial fibroblasts.
  • Marotte and colleagues published their study in Arthritis and Rheumatism, which provided new evidence on the role of ERK-1/2 signaling in regulating IL-18 bioactivity in RA synovial fibroblasts.

Statistics:

  • IL-18BPa levels were lower in RA synovial fluid than in OA synovial fluid by 31.2% (p < 0.01).
  • TNF-alpha-induced caspase 1 activity was determined to be 2.5-fold higher in RA synovial fibroblasts than in OA synovial fibroblasts (p < 0.05).
  • The study employed enzyme-linked immunosorbent assay (ELISA) to determine IL-18 and IL-18BPa levels in synovial fluid samples from patients with RA and OA.

Sources:

  • Marotte, H., et al. "Blocking ERK-1/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A." Arthritis and Rheumatism, vol. 62, no. 3, 2010, pp. 722-731.

Read more